AI & ChatGPT searches , social queries for BOSUTINIB
Search references for BOSUTINIB. Phrases containing BOSUTINIB
See searches and references containing BOSUTINIB!
Search references for BOSUTINIB. Phrases containing BOSUTINIB
See searches and references containing BOSUTINIB!BOSUTINIB
Chemical compound
Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous
Bosutinib
Pharmaceutical drug class
Bosutinib's activity was first described in 2001 and it was disclosed as an Abl kinase inhibitor in 2003. At first it was believed that bosutinib was
Bcr-Abl tyrosine-kinase inhibitor
Bcr-Abl_tyrosine-kinase_inhibitor
Type of blood cancer
approved in South Korea for people resistant to or intolerant of imatinib. Bosutinib received US FDA and EU European Medicines Agency approval on 4 September
Chronic_myelogenous_leukemia
Genetic abnormality in leukemia cancer cells
generation BCR::ABL1 TKI Generation Imatinib First-generation Dasatinib, Nilotinib, Bosutinib Second-generation Ponatinib, Asciminib Third-generation
Philadelphia_chromosome
American multinational pharmaceutical and biotechnology corporation
injectables such as the EpiPen. On September 4, 2012, the FDA approved bosutinib (Bosulif) for chronic myelogenous leukemia (CML), a rare type of leukemia
Pfizer
Medication
(ALK) Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase (JAK) Baricitinib
Elranatamab
Enzymes that block actions of protein kinases
VEGFR1/VEGFR2/VEGFR3/PDGFRB/c-KIT Pfizer Small molecule 2012 Renal cell carcinoma Bosutinib Bcr-Abl / SRC Pfizer Small molecule 2012 Chronic myelogenous leukemia
Protein_kinase_inhibitor
Chemical compound
tyrosine kinase inhibitors (IS-TKIs) (imatinib, nilotinib, dasatinib, or bosutinib). The main efficacy outcome measure was major molecular response rate
Asciminib
Monoclonal antibody
(ALK) Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase (JAK) Baricitinib
Mosunetuzumab
posterior leucoencephalopathy syndrome (rare) and polycythaemia (uncommon). Bosutinib PO Bcr-Abl and SRc kinase inhibitor. Chronic myeloid leukaemia Diarrhoea
List_of_antineoplastic_agents
Group of blood-based disorders
of FIP1L1-PDGFRA. Second generation tyrosine kinase inhibitors, e.g. bosutinib, sorafenib, and nilotinib, show little success in treating T674I FIP1L-PDGFRA
Clonal_hypereosinophilia
Mammalian protein found in humans
Other tyrosine kinase inhibitor drugs that are in clinical trials include bosutinib, bafetinib, Saracatinib(AZD-0530), XLl-999, KX01 and XL228. HSP90 inhibitor
Proto-oncogene tyrosine-protein kinase Src
Proto-oncogene_tyrosine-protein_kinase_Src
Type of therapy
Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib (Scemblix) Afatinib (Giotrif)
Targeted_therapy
Pharmaceutical drug classification
Utidelone L01EA01 Imatinib L01EA02 Dasatinib L01EA03 Nilotinib L01EA04 Bosutinib L01EA05 Ponatinib L01EA06 Asciminib L01EB01 Gefitinib L01EB02 Erlotinib
ATC_code_L01
Organic compound with a –C≡N functional group
tyrosine kinase inhibitor bosutinib, which is used in chronic myeloid leukemia. Crystal structures have been reported in which bosutinib is complexed with various
Nitrile
Enzyme
available inhibitors to treat CML are imatinib, dasatinib, nilotinib, bosutinib and ponatinib. Gastrointestinal stromal tumors (GIST) are known to withstand
Tyrosine_kinase
Class of drugs used to treat malignant tumors
toxicity Liver toxicity Hypertension Dasatinib (Sprycel) Nilotinib (Tasigna) Bosutinib Ponatinib Gefitinib (Iressa) Second-line treatment for advanced or metastatic
Antineoplastic
the first clinical inhibitor with GI50 of 9–60 nM in cancer cell lines. Bosutinib has been developed for the treatment of chronic myelogenous leukemia by
Src_inhibitor
Chemical compound
the LCK tyrosine kinase in cells displaying high level of lipid rafts. Bosutinib Dasatinib Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP
Saracatinib
(INN) Borofax bortezomib (USAN) Boruzu Bosatria bosentan (INN) Bosulif bosutinib (USAN, INN) botiacrine (INN) Botox Boudreaux's Butt Paste boxidine (INN)
List_of_drugs:_Bi–Bo
tyrosine kinase inhibitors such as imatinib, dasatinib, nilotinib, and bosutinib, which have increased 10-year survival rates for CML from 20% to 90%.
Hagop_Kantarjian
Italian oncologist and hematologist
develop at preclinical and clinical level another drug for CML named bosutinib. He is also the first researcher who (in June 2010) successfully treated
Carlo_Gambacorti-Passerini
Medical condition
mechanism, antiproliferative agents such as tyrosine kinase inhibitor bosutinib. However, results in clinical trials have shown mixed results, with studies
Autosomal dominant polycystic kidney disease
Autosomal_dominant_polycystic_kidney_disease
address new, mutated forms of BCR-ABL. These include dasatinib, nilotinib, bosutinib, and ponatinib. Cancer pharmacogenomics has also contributed to the understanding
Cancer_pharmacogenomics
BOSUTINIB
BOSUTINIB
BOSUTINIB
BOSUTINIB
BOSUTINIB
BOSUTINIB
BOSUTINIB
BOSUTINIB
BOSUTINIB